Proteins IL-31 , Human
- Known as:
- Proteins Interleukin-31 , Human
- Catalog number:
- C053
- Product Quantity:
- 10μg
- Category:
- -
- Supplier:
- Novoprotein
- Gene target:
- Proteins IL-31 Human
Related genes to: Proteins IL-31 , Human
- Gene:
- IL31 NIH gene
- Name:
- interleukin 31
- Previous symbol:
- -
- Synonyms:
- IL-31
- Chromosome:
- 12q24.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-11-06
- Date modifiied:
- 2014-11-19
Related products to: Proteins IL-31 , Human
Related articles to: Proteins IL-31 , Human
- Primary localized cutaneous amyloidosis (PLCA) is a chronic pruritic dermatological disorder characterized by amyloid deposits in the papillary dermis, significantly impairing patients' quality of life. Although the pathogenesis of PLCA is multifaceted, emerging evidence highlights the pivotal role of dysregulated cytokines, particularly the members of interleukin-6 (IL-6) cytokines family in PLCA. Oncostatin M (OSM) mediates keratinocyte proliferation through the STAT5-KLF7 axis upon OSMRβ engagement. Pathogenic variants in OSMR disrupt receptor dimerization, thereby suppressing signal transduction. These alterations together with cytokine dysregulation concomitantly elevate the expression of AHNAK and suppress that of Bcl-xL, which accelerate keratinocyte differentiation and apoptosis respectively, leading to the thickening of the stratum corneum and amyloid fibril deposition. Furthermore, dysregulated expression of chemokine monocyte chemoattractant protein-1 (MCP-1) by pathogenic variant in IL-31RA reduces monocyte-mediated clearance of amyloid fibrils, thereby promoting their pathological retention. The mechanisms of IL-31-mediated pruritus remain to be elucidated, given the conflicting observations that while some studies report wider cutaneous innervation in FPLCA patients, others demonstrate opposing results in general lichen amyloidosis patients. This review aims to synthesize recent advances in understanding PLCA pathogenesis with a focus on IL-31 and OSM cytokines network dysregulation especially driven by pathogenic variants, and provide critical insights for identifying therapeutic targets and put forward challenges in the future. - Source: PubMed
Publication date: 2026/04/24
Teng YiZhou XingliXiao YueLei KaixinDai LunzhiLi Wei - Lichen planopilaris (LPP) is an autoimmune cicatricial alopecia leading to irreversible follicular destruction. Interleukin-31 (IL-31) and its receptor complex (IL-31RA/OSMRβ) are implicated in neurogenic inflammation and pruritus in inflammatory dermatoses, including lichen planus. This study aimed to evaluate IL-31/IL-31RA expression in LPP and to investigate their associations with disease extent and pruritus. - Source: PubMed
Publication date: 2026/04/08
Gönüllü ÖyküErdem OzanÖzkanlı Sıdıka ŞeymaAtış GüldehanGürel Mehmet Salih - Nemolizumab reduces pruritus and skin lesions in patients with atopic dermatitis (AD), yet some patients develop cutaneous adverse events (CAEs) with increased serum thymus- and activation-regulated chemokine (TARC); mechanisms are unclear. - Source: PubMed
Publication date: 2026/03/12
Honryo AkiraMasuda ToshihiroNakamizo SatoshiTakafuji TakuyaMinami FuukaYonekura SatoruUchibayashi MidoriInoue KenichiKiyonari HiroshiYamanaka MasafumiIrie HiroyukiNakashima ChisaNakajima SaekoOtsuka AtsushiAsahina RyotaKabashima Kenji - Prurigo nodularis (PN) is a chronic, debilitating neuro-immunological skin disease characterized by intense pruritus and hyperkeratotic nodules. Nemolizumab, a novel IL-31 receptor alpha antagonist targeting the neural itch pathway, was investigated in PN. Two randomized phase 3 studies, the Olympia 1 and Olympia 2 trials, provided favorable efficacy and safety data for nemolizumab versus placebo in moderate-to-severe PN. After 16 weeks, a ≥4-point reduction in PP-NRS was achieved in 58.4% (Olympia 1) and 56.3% (Olympia 2) of nemolizumab patients compared to 16.7% and 20.9% in placebo groups, respectively (<0.001). Safety data showed no drug-related serious adverse events or organ toxicity. These trials were the first to clinically demonstrate IL-31 inhibition in PN. Nemolizumab represents a paradigm shift in PN therapy, acting as a potent "neuro-modulator" with rapid itch relief, often observed by Week 4. Future management may rely on disease endotypes to select between neural (IL-31) and immune (IL-4/13) blockade. - Source: PubMed
Publication date: 2026/02/24
Di Lernia VitoSticchi Alberto - Nemolizumab, an anti-IL-31 receptor A antibody, is licensed for atopic dermatitis and prurigo nodularis; its role in other chronic pruritus (CP) syndromes is uncertain. - Source: PubMed
Publication date: 2026/01/08
Shanshal MohammedUthayakumar Aarthy